lcar-m23
Cell therapyexperimental
Clinical trial activity
1 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 21, 2020 (NCT04562298)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- MesothelinImmunity, passive
MSLN immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04562298 | Phase 1 | Oct 21, 2020 | Anhui Medical University, East Clinical Center of Oncology, Fudan University, GenScript, Huazhong University of Science and Technology |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Anhui Medical University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| East Clinical Center of Oncology | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Fudan University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| GenScript | For profit | 1 | 0 | 1 | 2020 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 1 | 1 | 2020 |
5 organizations
Page 1 / 1